Renowned medtech research firm Life Science Intelligence has recognized a pioneering company for its work with developing a non-invasive and efficient lung cancer breath test.
In the firm’s newly released 2025 Emerging Innovators Report, Breath Diagnostics was named alongside over 500 industry leaders from 36 countries. The vast majority, 274, are based in the United States.
“Being recognized as part of this global group of innovators reinforces our commitment to advancing non-invasive, breath-based diagnostics and contributing to the future of healthcare,” Breath Diagnostics stated.
The LSI Emerging Innovators Report refers to Life Science Intelligence’s curated profiles and analyses of promising early-stage medtech startups tied to their Emerging Medtech Summits. It highlights vetted innovative companies, their technologies, market potential and funding updates to help investors and industry strategists identify opportunities.
“What sets our content apart is the depth of data and insights accumulated across the LSI ecosystem,” said LSI Senior Director of Market Intelligence, Nicholas Talamantes, last week, “helping cut through the noise and deepen our understanding of companies, markets, and industry trends that we share with customers.”
LSI has tracked emerging medtech companies since the mid-2000s through databases like the Emerging Medical Technologies Database. This evolved prominently with the launch of the organization’s Emerging Medtech Summit in 2020, where selected innovators present, leading to ongoing reports on summit participants, billions in alumni funding raised post-events and spotlights on influential startups.
Breath Diagnostics CEO Ivan Lo attended this year’s Emerging Medtech Summit in March. He educated the crowd about Breath Diagnostics’ OneBreath technology in Dana Point, California.
The company’s co-founder and Chief Medical Officer, renowned thoracic surgeon Dr. Victor van Berkel, recently shared his insights on a podcast for leading medical experts at the University of Louisville.
Read more: Breath Diagnostics completes install of advanced mass spectrometry system
OneBreath concisely explained
Essentially, OneBreath works by having a person breathe out once into a Tedlar bag. Breath provided by patients contains tiny amounts of natural gaseous chemicals that can change when lung cancer is present. Breath Diagnostics’ special MicroReactor captures these chemicals in the sample and turns them into stronger, easier-to-measure signals using a safe chemical process.
Advanced analysis then checks those signals to spot patterns linked to early-stage lung cancer, giving quick and accurate results without any needles, radiation or complicated steps. The entire process only takes approximately 10 minutes.
OneBreath has demonstrated 94 per cent sensitivity and 85 per cent specificity in multiple clinical trials involving over 800 patients. Recently, Breath Diagnostics augmented its screening technology regimen by installing a state-of-the-art mass spectrometry system from Waters Corp (NYSE: WAT) (FRA: WAZ) in its laboratory. In addition to lung cancer, OneBreath has shown great promise in detecting pneumonia onset and has potential applications for other lung diseases like COPD and tuberculosis.
Breath Diagnostics undertakes Reg CF capital raise
Breath Diagnostics is currently completing a fundraising campaign to help expedite deployment of its technology in the healthcare sector. The lung cancer screening company is almost 30 per cent of the way to its goal of raising US$3 million. As the addressable market for lung cancer screening technology is estimated to be worth over US$63 billion in the U.S. alone, future returns for investors could be significant.
For now, Breath Diagnostics is currently working toward developing a Clinical Laboratory Improvement Amendments (CLIA) laboratory developed test. This will eventually be followed by completing an extensive national lung cancer screening trial for OneBreath and attaining FDA approval.
Life Science Intelligence ranked Breath Diagnostics among medtech leaders such as ABILITY Neurotech, Caira Surgical and EBAMed. These companies have been breaking new ground with mobility solutions for patients with severe neurological conditions, orthopaedic robotics and targeted radiation therapy. They are a few of hundreds recognized for developing innovative technologies with several healthcare applications.
Accessing the full report from LSI will require you to pay US$1,995, but the intelligence firm has offered a free sample report to the public with info on a select group of companies.
Read more: Breath Diagnostics leaders promote their mission at Miami investment conference
Follow Rowan Dunne on LinkedIn
rowan@mugglehead.com
